UNI 0.00% $1.06 unilife medical solutions limited

& ems followers read this

  1. 635 Posts.
    I guess this announcement is designed to take some gloss off the EMS run.
    ========================================

    Company Announcement
    Unitract Retractable Syringe Widens Gap

    UNITRACT LIMITED 2003-05-06 ASX-SIGNAL-G
    HOMEX - Adelaide
    +++++++++++++++++++++++++
    Unitract Limited (ASX-UNI) ('Unitract') is pleased to announce that
    its project management team has successfully completed key feature
    enhancements of its Unitract Retractable Syringe, that increase the
    ability of the company to penetrate key target markets in Australia
    and overseas. Unitract has now completed all tooling and machine
    specifications prior to the commencement of production later this
    year.

    These enhancements have been developed following a period of
    consultation and discussions with global leaders in the health care
    industry, ensuring that the Unitract Retractable Syringe has the
    capacity to replace conventional syringes as the product of choice
    for the majority of injecting purposes.

    The Unitract Retractable Syringe combines independent Auto-Disable
    and Auto-Retraction features that together eliminate the risks of
    needle stick injuries and the re-use or sharing of syringes. The
    Auto-Disable feature, which unlike any other syringe technology, is
    independent of the retraction process to ensure it cannot be used
    again once the injection cycle has commenced.

    The Auto-Retraction feature is automatically activated once the
    injection process is complete. The retraction process is now
    performed by the use of a compressed spring contained within the
    collar of the syringe. This automatic retraction mechanism should
    obtain significant acceptance with users, as the pressure levels
    required to inject a dose will remain similar to a conventional
    syringe.

    The safe retraction of the needle into the barrel of the syringe will
    also now be followed by a second Auto-Disable function, with the
    needle being automatically offset to one side in the syringe barrel.
    This eliminates the chance of the needle being re-exposed, even by
    unconventional or malicious means.

    These product enhancements have not altered the ability of Unitract
    to supply the Unitract Retractable Syringe at a price that is
    competitive with conventional, non-retractable syringes. An
    international patent program has been introduced by Unitract to
    ensure that these product enhancements are protected. The new spring
    retention patent should add further value to the intellectual
    property held by Unitract, as its unique method of operation and
    design can be applied in products other than syringes.

    Mr Alan Shortall, CEO of Unitract stated "The unique ability of
    Unitract to provide an affordable product that shares the same steps
    of injection to a conventional syringe, yet requires no secondary
    action to engage its Auto-Disable and Auto-Retraction mechanisms,
    gives us an enormous market advantage. This places Unitract in an
    ideal position to capture a substantial share of the world market for
    syringes, which is currently in excess of 30 billion units per
    annum."

    "The Board has congratulated the Unitract project management team who
    have been able to complete these product enhancements as well as the
    tooling and machine specifications to see the Company move towards
    production by the end of this year."

    "The unique ability of Unitract to provide an affordable product that
    shares the same steps of injection to a conventional syringe, yet
    requires no secondary action to engage its Auto-Disable and
    Auto-Retraction mechanisms, gives us an enormous market advantage.
    The Board considers Unitract to be at the forefront of Auto-Disable
    and Auto-Retractable technologies and these recent developments have
    assisted in widening the gap between us and our competitors."

    For further media inquiries contact:

    Alan Shortall, CEO - 0418 906 733
    Stephen Allan - 0416 177 287


 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.